Creative Medical Technology (NASDAQ:CELZ) Shares Pass Below Fifty Day Moving Average – Time to Sell?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) shares crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.24 and traded as low as $2.21. Creative Medical Technology shares last traded at $2.23, with a volume of 96,464 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce”.

Creative Medical Technology Trading Down 0.4%

The firm has a market cap of $8.25 million, a price-to-earnings ratio of -1.04 and a beta of 1.84. The firm’s 50 day simple moving average is $2.24 and its two-hundred day simple moving average is $2.09.

Creative Medical Technology (NASDAQ:CELZ) last announced its earnings results on Friday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.01. As a group, equities research analysts anticipate that Creative Medical Technology Holdings, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Creative Medical Technology

A hedge fund recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is owned by hedge funds and other institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.